Immune cell engineering including adoptive transfer of T-cells genetically modified to express chimeric antigen receptors (CARs) specific for a selected tumor antigen such as CD19 in B-cell malignancies have demonstrated impressive antileukemic activity in patients with ALL, lymphoma, and chronic lymphocytic leukemia (182–185). This evidence concerns the gene CD19 and neoplasm.